MDxHealth SA Stock Euronext Bruxelles
Stocks
MDXH
BE0974461940
Biotechnology & Medical Research
| Market Cap | 19.29M 22.27M 17.98M 16.54M 31.22M 2.12B 31.57M 211M 82.93M 1.06B 83.65M 81.8M 3.51B | P/E 2026 * |
-0.67x | P/E 2027 * | -0.97x |
|---|---|---|---|---|---|
| Enterprise Value | 141M 163M 132M 121M 229M 15.51B 231M 1.55B 607M 7.76B 613M 599M 25.7B | EV / Sales 2026 * |
1.47x | EV / Sales 2027 * | 1.48x |
| Free-Float |
88.87% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: MDxHealth SA
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 2019-02-17 | |
Ron Kalfus
DFI | Director of Finance/CFO | 52 | 2019-07-21 |
Miriam Reyes
COO | Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Hilde Windels
BRD | Director/Board Member | 61 | 2017-10-31 |
Koen Hoffman
CHM | Chairman | 58 | 2017-12-31 |
| Director/Board Member | 64 | 2019-02-17 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -2.58% | - | - | 22.27M | |
| +0.78% | -0.91% | +3.59% | +15.26% | 48.57B | |
| +1.98% | +9.05% | +413.94% | +532.17% | 41.95B | |
| +3.44% | -4.65% | +28.34% | +8.81% | 38.85B | |
| +1.40% | +0.10% | +6.61% | +61.93% | 37.24B | |
| +2.42% | +5.72% | +12.38% | +44.79% | 30.67B | |
| -0.16% | -3.11% | - | - | 16.1B | |
| +2.20% | +0.48% | +34.71% | +127.15% | 16.41B | |
| +0.23% | +1.81% | +8.11% | +18.94% | 13.97B | |
| +4.25% | -8.23% | -1.49% | -35.46% | 12.62B | |
| Average | +1.64% | -0.78% | +63.27% | +96.70% | 28.48B | |
| Weighted average by Cap. | +1.81% | -0.12% | +82.94% | +120.65% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 95.89M 111M 89.39M 82.21M 155M 10.53B 157M 1.05B 412M 5.27B 416M 407M 17.45B | 108M 125M 101M 92.51M 175M 11.85B 177M 1.18B 464M 5.93B 468M 458M 19.63B |
| Net income | -28M -32.32M -26.1M -24M -45.31M -3.07B -45.82M -307M -120M -1.54B -121M -119M -5.09B | -17.95M -20.72M -16.73M -15.39M -29.05M -1.97B -29.38M -197M -77.17M -986M -77.83M -76.12M -3.27B |
| Net Debt | 122M 141M 114M 105M 197M 13.39B 200M 1.34B 524M 6.7B 529M 517M 22.19B | 140M 162M 131M 120M 227M 15.38B 229M 1.53B 602M 7.7B 608M 594M 25.49B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
